Latest News for: egfr inhibitor
Edit
AstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical (Form 6-K) (AstraZeneca plc)
Public Technologies 14 Jul 2026
Edit
AstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical (AstraZeneca plc)
Public Technologies 14 Jul 2026
AstraZeneca has entered into an exclusive license agreement with Dizal Pharmaceutical Co., Ltd for Zegfrovy (sunvozertinib), a novel oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer.
Edit
EGFR Inhibitors Market to Witness Upsurge in Growth at a CAGR of 7.9% During the Forecast Period (2026-2036) Owing to the Entry of Next-generation TKIs, ADCs, and Combination Strategies with Immunotherapy| DelveInsight
PR Newswire 15 Jun 2026
... Analysis EGFR Inhibitors Market Size and Trends EGFR Inhibitors Market Opportunity EGFR Inhibitors Market Unmet Needs KOL's Views on EGFR Inhibitors EGFR Inhibitors Market Access and Reimbursement.
Edit
EGFR Inhibitors-induced Skin Disorders Market is Projected to Grow by 2036 Owing to the Rising ...
GetNews 05 Jun 2026
The market dynamics for EGFR Inhibitors-induced Skin Disorders are witnessing significant growth driven by the increasing use of EGFR inhibitors across multiple cancer indications, rising incidence of ...
- 1